Skip to content
ATLAS PREP HQ
Cognitive

Selank

Thr-Lys-Pro-Arg-Pro-Gly-Pro, a synthetic tuftsin analogue

Synthetic tuftsin-analog research focused on anxiety, stress regulation, and cognitive function.

Limited Human Evidence

Route

Intranasal has the stronger human-use history

Common format

5 mg vial

Research focus

anxiety

Evidence level

Limited Human Evidence

Typical cycle

4 weeks

Cognitive research motifCognitive

Selank in 30 seconds

Atlas Fast Read

What it is

Thr-Lys-Pro-Arg-Pro-Gly-Pro, a synthetic tuftsin analogue

Why people care

Synthetic tuftsin-analog research focused on anxiety, stress regulation, and cognitive function.

Human evidence

Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

Biggest misconception

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Bottom line

Selank has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims.

Overview

What is Selank?

Selank is thr-Lys-Pro-Arg-Pro-Gly-Pro, a synthetic tuftsin analogue. Synthetic tuftsin-analog research focused on anxiety, stress regulation, and cognitive function.

Selank was developed in Russian peptide-neurobiology programs as a synthetic analogue of the immunopeptide tuftsin. It has local clinical use/history in Russia, but international replication and large modern trials remain limited.

Mechanism

How it works

Proposed to modulate GABAergic signaling, neurotrophins, and monoamine-related gene expression while also having immunopeptide activity. Human mechanistic data are much thinner than the Russian clinical literature suggests.

Research areas

anxietystress resiliencecognitionGABA/neurotrophin signaling

Evidence

What does the evidence actually say?

Limited Human Evidence

Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Small human studies and Russian clinical experience suggest anxiolytic effects, but the literature is relatively limited, regionally concentrated, and lacks large independent confirmatory trials. Human evidence is therefore limited rather than absent.

Preclinical evidence

Animal and cell studies report anxiolytic effects, changes in GABA-related signaling, neurotrophins, and stress-response genes. Human evidence exists but is less extensive than the preclinical/mechanistic narrative.

Knowledge gaps

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

community sources SC reference: 300–500 mcg/day. Much of the human literature and Russian use is intranasal and uses formulation-specific dosing, so routes are not directly interchangeable.

Frequency

Once daily in the community SC protocol; intranasal studies may use divided doses.

Timing

Often daytime or divided; adjust to sleep/mood effects. No internationally established standard.

Route

Intranasal has the stronger human-use history; Community sources also list subcutaneous research use.

Cycle length

4 weeks

Reconstitution

Community reference: 0.5 mL bacteriostatic water per 5 mg vial = 10 mg/mL for SC research use.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C; avoid repeated freeze-thaw.

Monitoring

Anxiety and validated mood scales, sedation/activation, sleep, BP and adverse effects; no compound-specific lab panel is validated.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Systematic human safety data are limited. Reported or plausible effects include headache, dizziness, fatigue, irritability, sleep changes, nausea and injection/nasal-site irritation depending on route.

Contraindications

No validated broad contraindication profile exists. Avoid unsupervised use in pregnancy/breastfeeding, severe psychiatric instability, seizure disorders or major neurologic disease unless the research/clinical protocol specifically addresses it.

Interactions

Formal interaction studies are limited. CNS-active medicines, sedatives, stimulants, antidepressants, anxiolytics and anticonvulsants may alter or obscure effects and should be reviewed clinically.

Stacks

Common stacks

Selank + Semax

Common pairing intended to balance anxiolytic and cognitive/neurotrophic effects.

Combination evidence is limited and not independently validated.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Selank has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims. The most defensible use of the literature is to separate what has actually been measured in people from what is still extrapolated from mechanism or animal work.

More in Cognitive

Cognitive

Adamax

Semax-derived nootropic research focused on BDNF signaling, neuroprotection, and cognitive performance.

Read guide

Cognitive

Cerebrolysin

Neurotrophic peptide mixture researched for neuroprotection, neuronal recovery, and cognitive function.

Read guide

Cognitive

PE-22-28

Experimental TREK-1 antagonist peptide research focused on neuroplasticity and mood-related pathways.

Read guide